

(21) International Application Number: PCT/US97/22096 (22) International Application Number: PCT/US97/22096 (22) International Filing Date: 26 November 1997 (26.11.97) (23) Priority Data: 60093,1860 27 November 1996 (27.11.96) US 60093,126 17 September 1997 (17.09.97) US 60093,126	51) International Patent Classification 6:		1) International Publication N	umber: WO 98/2363
 P.O. Box 4433, Houston, TX 77210 (US). P.O. C. G. G. G. G. G. G. G. H. L. I. I.	C07K 14/435, A61K 38/17	A3	3) International Publication D	ate: 4 June 1998 (04.06.98
30) Priority Data: 60/031,860 17 September 1996 (27.11.96) US 60/031,860 17 September 1997 (17.09.97) US 17 September 1997 (17.09.97) US 18 P. CA, C.H., C.N., C.U., C.Z., DE, D.K., EE, ES, FI, GB, GB, GH, GH, DL, DL, III, S. J.P., KEE, KG, K.P., KR, KZ, LC, LI LR, LS, L.T., LU, LV, MD, MG, MK, MN, MW, MX, NL THE UNIVERSITY OF FLORIDA [US/US]: 223 Grinter Hall, Gainesville, FL 32611 (US). THE REGENTS OF THE UNIVERSITY OF SULFOWNIA [US/US]: 223 Grinter Hall, Gainesville, FL 32611 (US). THE REGENTS OF THE UNIVERSITY OF SULFOWNIA [US/US]: 223 Grinter Hall, Gainesville, FL 32611 (US). THE REGENTS OF THE UNIVERSITY OF CARLETONIA (US/US): 202 Losis and Experiment (A.S. P. T. T. UA, UG, UZ, VN, YU, ZW, ARIPO patent (AM, AZ BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE FL SEN, ES, LT, TR, BG, GR, IE, TI, UM, MC, NC, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GB ML, MR, NE, SN, TD, TG). The Company of th	,			
54) Title: ShK TOXIN COMPOSITIONS AND METHODS OF USE 57) Abstract Disclosed are methods and compositions comprising DNA segments, and proteins derived from sea anemone species. Moratteularly, it concerns the novel ShK toxin, ShK toxin analogs, chemically-modified toxin analogs, and nucleic acid segments encodin shK toxin from Stkhodarcyle hellandhus. Various methods for making and using these DNA segments, DNA segments encodin synthetically-modified ShK toxins, and native and synthetic ShK peptides are disclosed, such as, for example, the use of DNA segments againsative probes and templates for protein production, and the use of proteins, fusion protein carriers and peptides in various immunologic.	60/031,860 27 November 1996 (27. 60/059,126 17 September 1997 (17. 71) Applicants: UNIVERSITY OF FLORIDA [US/U ter Hall, Gainesville, FL 32611 (US). THE RI THE UNIVERSITY OF CALIFORNIA (US/U side Drive, Oakland, CA 94612-3550 (US). BA SCIENCE, INC. (US/US): 3700 Horizon Dr Prussia, Pa 19406 (US). BIOMOCLECULAR INSTITUTE (UJA/UJ). 343 Royal Farnde, Fa 3052 (AU). 72) Javentors: KEM, William, R.; 1809 Northwest Gainesville, FL 32605 (US). PENNINGTON, 32 Delwood Drive, Cherry Hill, NJ 08002 (US) Raymond, S.; 353 Royal Pamde, Pariville, VIC CHANDY, George, K.; 1218 Morningside D Beach, CA 92651 (US). KALMAN, Kstalin;	S]; 223 Gri EGENTS (S); 300 Lak CHEM BIG ive, King RESEARC rksville, VI	BY, CA, CH, CN, CL GH, HU, ID, IL, IS, IR, LS, LT, LU, LV, NZ, PL, PT, RO, RU TR, TT, UA, UG, UZ KE, LS, MW, SD, SZ, BY, KG, KZ, MD, RU CH, DE, DK, ES, IT, PT, SED, OATP, Date: ML, MR, NE, SN, TO! Published With international search Before the expiration of it and to be republished in it	J. CZ, DE, DK, EE, ES, FI, GB, GI, PK, KE, KE, KE, LC, LI MD, MG, MK, MN, MW, MX, NK, SD, SE, SG, SI, SK, SL, TJ, TN, VN, YU, ZW, ARIPO patent (GA, ZW, Eurasian patent (AM, AZ, TJ, TM), European patent (AT, BI FR, GB, GR, EI, TI, LU, MC, (BF, BJ, CF, CG, CI, CM, GA, GP, TG). The time limit for amending the clair he event of the receipt of amendment international search report:
	57) Abstract Disclosed are methods and compositions comparticularly, it concerns the novel ShK toxin, ShK toxin to ShK toxin from Sthehodacybe hellanthus. You will be she toxin shift toxin with control to the shift toxin from Sthehodacybe hellanthus. You will be shift to	orising DN. in analogs, is methods hetic ShK p	segments, and proteins derived smically-modified toxin analogs, making and using these DNA ides are disclosed, such as, for e	and nucleic acid segments encodin segments, DNA segments encodin xample, the use of DNA segments a
	57) Abstract Disclosed are methods and compositions comparticularly, it concerns the novel ShK toxin, ShK toxin to ShK toxin from Sthehodacybe hellanthus. You will be she toxin shift toxin with control to the shift toxin from Sthehodacybe hellanthus. You will be shift to	orising DN. in analogs, is methods hetic ShK p	segments, and proteins derived smically-modified toxin analogs, making and using these DNA ides are disclosed, such as, for e	and nucleic acid segments encoding segments, DNA segments encoding xample, the use of DNA segments a
	57) Abstract Disclosed are methods and compositions comparticularly, it concerns the novel ShK toxin, ShK toxin to ShK toxin from Sthehodacybe hellanthus. You will be she toxin shift toxin with control to the shift toxin from Sthehodacybe hellanthus. You will be shift to	orising DN. in analogs, is methods hetic ShK p	segments, and proteins derived smically-modified toxin analogs, making and using these DNA ides are disclosed, such as, for e	and nucleic acid segments encoding segments, DNA segments encoding xample, the use of DNA segments a
	57) Abstract Disclosed are methods and compositions comparticularly, it concerns the novel ShK toxin, ShK toxin to ShK toxin from Sthehodacybe hellanthus. You will be she toxin shift toxin with control to the shift toxin from Sthehodacybe hellanthus. You will be shift to	orising DN. in analogs, is methods hetic ShK p	segments, and proteins derived smically-modified toxin analogs, making and using these DNA ides are disclosed, such as, for e	and nucleic acid segments encodin segments, DNA segments encodin xample, the use of DNA segments a
	57) Abstract Disclosed are methods and compositions comparticularly, it concerns the novel ShK toxin, ShK toxin to ShK toxin from Sthehodacybe hellanthus. You will be she toxin shift toxin with control to the shift toxin from Sthehodacybe hellanthus. You will be shift to	orising DN. in analogs, is methods hetic ShK p	segments, and proteins derived smically-modified toxin analogs, making and using these DNA ides are disclosed, such as, for e	and nucleic acid segments encodin segments, DNA segments encodin xample, the use of DNA segments a
	57) Abstract Disclosed are methods and compositions comparticularly, it concerns the novel ShK toxin, ShK toxin to ShK toxin from Sthehodacybe hellanthus. You will be she toxin shift toxin with control to the shift toxin from Sthehodacybe hellanthus. You will be shift to	orising DN. in analogs, is methods hetic ShK p	segments, and proteins derived smically-modified toxin analogs, making and using these DNA ides are disclosed, such as, for e	and nucleic acid segments encodin segments, DNA segments encodin xample, the use of DNA segments a

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Amenia	PI	Pinland	LT	Lithunnia	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BB	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	lceland	MW	Malawi	US	United States of Americ
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	Pi,	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DR	Germany	u	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Interr nai Application No PCT/US 97/22096

A CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/435 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K A61K

mentation searched other than minimum documentation to the extent that evol documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
M.W. PENNINGTON: "Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lyphocytes and rat brain" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 219, February 1996, ORLANDO, FL US, pages 696-701, XP062061813	1,2,4-9, 15-19, 22,23, 26-36, 39,41-46
see the whole document	3,10-14, 20,21, 24,25, 37,38,40
see page 699, paragraph 2 - paragraph 3; table 1 -/	37,30,40
	M.W. PENNINGTON: "Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lyphocytes and rat brain" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 219, February 1996, ORLANDO, FL US, pages 696-701, XP002061813 cited in the application see the whole document see page 699, paragraph 2 - paragraph 3; table 1

X Further documents are listed in the continuation of box C.

X Patent family members are listed in annex.

Special categories of cited documents :

document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or

"P" document published prior to the international filing date but later than the priority date claimed

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

To later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the documents is combined with one or more other such documents, such combined with one or more other such documents, such combination being obvious to a person skilled in the art.

20. 05. 1998

"&" document member of the same patent family Date of mailing of the international search report

Date of the actual completion of the international search

9 April 1998 Name and mailing address of the ISA

1

European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Authorized Officer Cervigni, S

Form PCT/ISA/210 (second sheet) (July 1992)

Inte onal Application No PCT/US 97/22096

		PC1/US 97/22096
C.(Continue Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Hejevant to claim No.
X,0	M.W. PENNINGTON ET AL: "Identification of essential residues in the potassium channel inhibitor ShK toxin: analysis of monosubstituted analogs" PEPTIDES: CHEMISTRY, STRUCTURE AND BIOLOGY - PROCEEDINGS OF THE 14TH AMERICAN PEPTIDE SYMPOSIUM,	1,2,4-9, 15-19, 22,23, 26-36, 39,41-46
Y	June 1995, ESCOM - LEIDEM, NL, pages 192-194, XPO02061814 see the whole document	3,10-14, 20,21, 24,25,
	see page 194, last paragraph; table 1	37,38,40
x	J.E. TUDOR ET AL.: "Solution structure of Shk toxin, a novel potassium channel inhibitor from a sea anemone" NATURE STRUCTURAL BIOLOGY. vol. 3, no. 4, April 1996. pages 317-320, XP002061901	1-4,7,8, 15-19, 22,23, 26-30, 32, 34-40,
Y	see the whole document see page 317, column 2, line 4 - line 9	45,46 3,10-14, 20,21, 24,25, 37,38,40
х	M.W. PENNINGTON ET AL.: "Chemical synthesis and characterisation of ShK toxin" INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, vol. 46, 1995, COPENHAGEN DK, pages 354-358, XP002061815	1,2,4,7, 8,15-19, 22,23, 26-30, 32, 34-36, 39,45,46
Y	cited in the application see the whole document	3,10-14, 20,21, 24,25, 37,38,40
Y	WO 88 06451 A (XOMA CORP) 7 September 1988	3,10-14, 20,21, 24,25, 37,38,40
	see the whole document	37,50,10
Y	EP 0 219 716 A (TOA NEMRYO KOGYO KK ;TSURU SUMIAKI (JP)) 29 April 1987	3,10-14, 20,21, 24,25, 37,38,40
	see the whole document	
}		

In. . lational application No. PCT/US 97/22096

Box i	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	emational Search Report has not been established in respect of contain claims under Article 17(2)(e) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	see FURTHER INFORMATION sheet PCT/ISA/210
2. [Claims Non.: beause they relate to parts of the Intermetional Application that do not comply with the prescribed requirements to such en extent that no meaningful International Search can be carried out, specifically:
з. 🗀	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box ii	Observations where unity of invention is tacking (Continuation of item 2 of first sheet)
This Inte	emational Searching Authority found multiple inventions in this international application, as follows:
İ	
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchabte claims.
2. 🗆	As all searchable claims could be searched without effort justifying an edditional fee, this Authority did not invite payment
	of any edditional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international Search Report overso only those obtains for which fees were poid, specifically claims Nos.:
4. 🗆	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protast The additional search (see were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

	International Application No. PCT/US 97 /22096
FURTHER INFORMATION CONTINUED FROM PCT	ISAV 210
Remark : Although claims 1-11, 22-2 are directed to a method of treatms search has been carried out and bas compound/composition.	25, 29-40 and at least in part 45-46 ent of the human/animal body, the sed on the alleged effects of the
	*

	Information on patent family me	Inter: nal Application No PCT/US 97/22096			
Patent document citéd in search report	Publication date	Patent family member(s)		Publication date	
WO 8806451 A	07-09-88	AU 619740 AU 1421488 DE 3875300 EP 0303681 JP 1502909	3 A 5 A 1 A	06-02-92 26-09-88 19-11-92 22-02-89 05-10-89	
EP 0219716 A	29-04-87	JP 1946825 JP 6069959 JP 62072621 AU 6315986) B	10-07-95 07-09-94 03-04-87 02-04-87	
× "					
4					
. ,					
		,			
. %					
•		* .			